Literature DB >> 15261459

STAT-1 is activated by IL-4 and IL-13 in multiple cell types.

I-Ming Wang1, Huamao Lin, Samuel J Goldman, Michiko Kobayashi.   

Abstract

While interleukin-4 (IL-4) and interleukin-13 (IL-13) can utilize a common receptor, composed of IL-4Ralpha and IL-13Ralpha1, IL-4 can also signal through a receptor with IL-4Ralpha and the common gamma chain (gammaC) as its subunits. IL-4 and IL-13 have been reported to elicit similar biological effects in a number of settings, including stimulating Ig isotype switching to IgE and inducing chemokines and cytokines in a variety of cell types whereas, depending on the receptor expression on responder cells, differential effects such as induction of type II helper T cell differentiation by IL-4 but not by IL-13 are also well documented. Recent data suggest distinct roles for these two cytokines in the 'in vivo' pathology of airway inflammatory diseases such as asthma. In this study, we examined the possibility of differential signaling by IL-4 and IL-13 on cells of the airway, by comparing expression of receptor chains and activation of different Signal Transducer and Activator of Transcription (STAT) family members. Five primary cultured cell lines representing four non-immune human lung tissue cell types (smooth muscle, epithelium, endothelium, and fibroblast) were utilized. While we readily detected expression of IL-4 Ralpha and IL-13Ralpha1 in all five cell lines, gammaC was not detectable in any of these cell lines. Consistent with previous reports, we detected STAT-6 activation in all five airway tissue cell lines examined in response to both cytokines. In addition, we also consistently detected STAT-1 activation in all of these cells. This observation was extended to include lymphoid as well as myeloid cells that express also gammaC chain. In conclusion, while the study found no differences in STAT activation in response to the two cytokines, the data show that in addition to STAT-6 activation, STAT-1 activation is also a part of the integral signaling pathways utilized by IL-4 and IL-13.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15261459     DOI: 10.1016/j.molimm.2004.04.027

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  20 in total

1.  Interleukin (IL)-4 and IL-13 up-regulate monocyte chemoattractant protein-1 expression in human bronchial epithelial cells: involvement of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2 and Janus kinase-2 but not c-Jun NH2-terminal kinase 1/2 signalling pathways.

Authors:  W K Ip; C K Wong; C W K Lam
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

2.  Altered phosphorylated signal transducer and activator of transcription profile of CD4+CD161+ T cells in asthma: modulation by allergic status and oral corticosteroids.

Authors:  Yael Gernez; Rabindra Tirouvanziam; Khoa D Nguyen; Leonard A Herzenberg; Alan M Krensky; Kari C Nadeau
Journal:  J Allergy Clin Immunol       Date:  2007-10-24       Impact factor: 10.793

3.  Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment.

Authors:  Sujita Sukumaran; Norihiro Watanabe; Pradip Bajgain; Kanchana Raja; Somala Mohammed; William E Fisher; Malcolm K Brenner; Ann M Leen; Juan F Vera
Journal:  Cancer Discov       Date:  2018-06-07       Impact factor: 39.397

4.  Receptor density is key to the alpha2/beta interferon differential activities.

Authors:  Ignacio Moraga; Daniel Harari; Gideon Schreiber; Gilles Uzé; Sandra Pellegrini
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

Review 5.  Proinflammatory Pathways in the Pathogenesis of Asthma.

Authors:  R Stokes Peebles; Mark A Aronica
Journal:  Clin Chest Med       Date:  2019-03       Impact factor: 2.878

6.  Myeloid Slc2a1-Deficient Murine Model Revealed Macrophage Activation and Metabolic Phenotype Are Fueled by GLUT1.

Authors:  Alex J Freemerman; Liyang Zhao; Ajeeth K Pingili; Bin Teng; Alyssa J Cozzo; Ashley M Fuller; Amy R Johnson; J Justin Milner; Maili F Lim; Joseph A Galanko; Melinda A Beck; James E Bear; Jeremy D Rotty; Lavanya Bezavada; Heather S Smallwood; Michelle A Puchowicz; Juan Liu; Jason W Locasale; Douglas P Lee; Brian J Bennett; E Dale Abel; Jeff C Rathmell; Liza Makowski
Journal:  J Immunol       Date:  2019-01-18       Impact factor: 5.422

7.  Mesenchymal cell survival in airway and interstitial pulmonary fibrosis.

Authors:  James C Bonner
Journal:  Fibrogenesis Tissue Repair       Date:  2010-08-25

8.  IL-4 receptor as a bridge between the immune system and muscle in experimental myasthenia gravis I: up-regulation of muscle IL-15 by IL-4.

Authors:  Sabrina Shandley; Sonia Martinez; Keith Krolick
Journal:  Clin Immunol       Date:  2009-04-22       Impact factor: 3.969

Review 9.  Interleukin-13: prospects for new treatments.

Authors:  C E Brightling; S Saha; F Hollins
Journal:  Clin Exp Allergy       Date:  2009-10-30       Impact factor: 5.018

10.  Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain.

Authors:  Thirumalai R Ramalingam; John T Pesce; Faruk Sheikh; Allen W Cheever; Margaret M Mentink-Kane; Mark S Wilson; Sean Stevens; David M Valenzuela; Andrew J Murphy; George D Yancopoulos; Joseph F Urban; Raymond P Donnelly; Thomas A Wynn
Journal:  Nat Immunol       Date:  2007-12-09       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.